Celcuity Inc. (CELC): Price and Financial Metrics

Celcuity Inc. (CELC): $17.54

0.30 (+1.74%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

CELC Price/Volume Stats

Current price $17.54 52-week high $22.19
Prev. close $17.24 52-week low $8.39
Day low $16.96 Volume 405,100
Day high $17.67 Avg. volume 218,165
50-day MA $17.54 Dividend yield N/A
200-day MA $13.12 Market Cap 534.15M

CELC Stock Price Chart Interactive Chart >


Celcuity Inc. (CELC) Company Bio


Celcuity LLC, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. It develops CELx tests to diagnose breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is based in Minneapolis, Minnesota.


CELC Latest News Stream


Event/Time News Detail
Loading, please wait...

CELC Latest Social Stream


Loading social stream, please wait...

View Full CELC Social Stream

Latest CELC News From Around the Web

Below are the latest news stories about CELCUITY INC that investors may wish to consider to help them evaluate CELC as an investment opportunity.

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

MINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR (PAM) inhibitors in breast cancer cell lines during a poster session at the 2023 San Antonio Breast Cancer Symposium (SABCS). The preclinical studies evaluated gedatolisib, a pan-PI3K/mTOR inhibitor, and PAM inhibitors that selectivel

Yahoo | December 6, 2023

Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium

MINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract accepted for a poster presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS) is now available on the SABCS website. The 2023 San Antonio Breast Cancer Symposium (SABCS) is being held virtually and in-person from December 5-9, 2023. The presentation will include potency and effica

Yahoo | December 1, 2023

Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference

MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the 6th Annual Evercore ISI HealthCONx Conference held in Miami. Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for a fireside chat at 12:30 p.m. ET on Wednesday, November 29, 2023. A live webcast of the event will be available using this weblin

Yahoo | November 22, 2023

Celcuity Inc. (NASDAQ:CELC) Q3 2023 Earnings Call Transcript

Celcuity Inc. (NASDAQ:CELC) Q3 2023 Earnings Call Transcript November 13, 2023 Operator: Greetings, and welcome to the Celcuity Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It […]

Yahoo | November 14, 2023

Q3 2023 Celcuity Inc Earnings Call

Q3 2023 Celcuity Inc Earnings Call

Yahoo | November 14, 2023

Read More 'CELC' Stories Here

CELC Price Returns

1-mo -1.35%
3-mo 21.47%
6-mo 68.65%
1-year 82.52%
3-year -30.73%
5-year -18.61%
YTD 20.38%
2023 4.00%
2022 6.22%
2021 44.00%
2020 -13.91%
2019 -55.65%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!